The decline in financial performance was primarily attributed to a decrease in sales of cosmetic ingredients, significantly impacted by excess inventory held by the company's largest distributor, Ashland Specialty Ingredients (ASI). This overstock situation led to reduced order quantities from ASI throughout the year. Additionally, the company faced decreased global demand for its products, particularly in China, where competition from local producers and global tariffs further hindered sales.
In response to these challenges, United-Guardian has been actively collaborating with its distributor in China to regain lost market share. The company is implementing competitive pricing strategies, differentiating its products, and exploring new markets where cost pressures are less pronounced.
On a more positive note, the company reported increases in sales of pharmaceuticals and medical lubricants, which rose by 15% and 4%, respectively, compared to the previous year. The growth in medical lubricants was driven by heightened demand from two major contract manufacturer customers in China. Furthermore, the increase in pharmaceutical sales was attributed to higher sales to national drug wholesalers and a decrease in Medicare rebates.
United-Guardian has also initiated a new marketing strategy aimed at expanding domestic sales of its product Renacidin, which has recently received approval from two major pharmacy benefit managers for inclusion on additional drug formularies. This initiative is expected to enhance patient access and support the product's long-term commercial growth.
Despite the challenges faced in 2025, United-Guardian remains optimistic about future growth opportunities, particularly through its new marketing and distribution agreements for cosmetic ingredients and the ongoing demand for its pharmaceutical products.
